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Abstract
Background: For patients undergoing liver resection for colorectal metastases, specific clinico-
pathological variables have been shown to be prognostic at baseline. This study analyses how the
prognostic capability of these variables changes in a conditional survival model.
Methods: Retrospective review of a prospectively maintained database of patients who underwent an
R0 resection of colorectal liver metastases from 1994 to 2004 at a single institution.
Results: In total, 807 patients were identified, with an 87-month median follow-up for survivors. Five-
and 10-year disease-specific survivals (DSS) were 68% and 55%, respectively. The probability of
further survival increased as the survival time increased. For 3-year survivors (n = 504), DSS were no
longer significantly different between patients with a low (0–2) or high (3–5) clinical risk score (CRS,
P = 0.19). On multivariate analysis, independent predictors of DSS for 3-year survivors were recurrence
within the first 3 years after a liver resection, a pre-operative carcinoembryonic antigen (CEA)
>200 ng/ml and disease-free interval <12 months prior to the diagnosis of liver metastasis. However, for
those patients who were recurrence free at 1 year, no clinico-pathological variables retained prognostic
significance.
Discussion: After 3 years of DSS and 1 year of recurrence-free survival, baseline clinico-pathological
variables have a limited ability to predict future survival. Early post-operative recurrence appears to be the
most useful single clinical feature in estimating conditional DSS.
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Introduction
The liver is the most common site of distant metastasis from
colorectal cancer, developing in approximately half of patients. A
hepatic resection has become the standard therapy for resectable
metastases, and remains the best chance for long-term survival
and only chance of a cure.1 Previous studies have demonstrated
that patients can be considered cured of their metastatic disease if
they remain disease-free 10 years after a liver resection,2 which
occurs in only about 20–25% of resected patients. On the other
hand, 75% of all recurrences occur within the first 2 years post-
operatively.3 Therefore, numerous studies have attempted to
define clinical and histopathological variables associated with
prognosis.4–15 These variables include nodal status and degree of
differentiation of the primary colorectal tumour, synchronous
compared with metachronous tumours, number and size of
hepatic metastases and pre-operative concentration of carci-
noembryonic antigen (CEA). From such variables, prognostic
scoring systems have been developed, including the Clinical Risk
Score (CRS)6 and the Memorial Sloan-Kettering Cancer Center
(MSKCC) nomogram.16 While these systems have been validated
at other institutions,17–19 their general applicability remains uncer-
tain.15 Furthermore, substantial residual unexplained variability
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exists in these models, as their concordance indices (CI) are about
0.6.13,15,20
Traditional survival estimates are calculated from a single point
in time, usually the time of diagnosis or operation. In contrast,
conditional survival (CS) is defined as the probability of future
survival based on survival time already accumulated, and includes
only individuals who have survived to a pre-determined time of
interest. CS has been studied across national populations21–24 and
in specific cancers, including colorectal cancer25–28 and pancreatic
adenocarcinoma.29,30 Only one study, by Nathan et al.20, has spe-
cifically analysed CS in patients who have undergone a liver resec-
tion for colorectal metastases. They demonstrated that CS
improved over time but that the performance of various prognos-
tic scoring systems declined as survival time increased. Several
previous studies have demonstrated in other cancers28,31–33 that the
prognostic value of clinicopathological variables diminishes as the
survival time increases.
To date, analyses of conditional survival in cancer patients have
examined all survivors, whether or not recurrence has occurred.
No study has specifically examined patients who remain without
evidence of recurrent disease after a curative resection, and how
the prognostic ability of baseline risk factors changes as survival
time increases. This is particularly relevant in patients who have
undergone a curative-intent liver resection for colorectal metas-
tases given the significant chance of recurrence,3 but also of long-
term survival after recurrence owing to improved efficacy of
modern chemotherapy and, in a minority of cases, resection of
recurrent metastatic disease.
In this study of patients who have undergone a margin-negative
liver resection for colorectal metastases, we sought to confirm that
the prognostic value of risk-scoring systems decreased as the sur-
vival time increased. Further, we hypothesized that any clinico-
pathological factors would have a limited prognostic ability to
predict future overall and recurrence-free survival, specifically in
the subset of patients who had survived without evidence of
recurrent disease.
Materials and methods
Patients and data collection
With approval of the Institutional Review Board and in accord-
ance with Health Insurance Portability and Accountability Act
regulations, a prospectively maintained hepatobiliary database
was used to identify all patients who underwent a resection of
colorectal liver metastases at MSKCC from 1994–2004. Post-
operative deaths (within 90 days of a hepatectomy) and those
patients with margin-positive resections were excluded. Guide-
lines for resectability were medical fitness for a major laparotomy,
no evidence of disseminated disease and a resection strategy
encompassing all liver disease with an adequate remnant liver for
recovery. A pre-operative extent-of-disease evaluation included
chest/abdominal/pelvic computed tomography, and colonoscopy.
18F-fluorodeoxyglucose-positron emission tomography/CT
(18FDG PET-CT) was used selectively. All patients were evaluated
at a weekly multidisciplinary conference.
Variables studied included age, gender, site and node status of
the primary, presence of lymphovascular invasion (LVI) or
perineural invasion (PNI), synchronous compared with meta-
chronous metastases, disease-free interval (DFI; defined as time
elapsed from a primary resection to a hepatic recurrence), pre-
hepatectomy CEA level, the presence or absence of bilobar disease,
and the size and number of hepatic tumours. Post-operative vari-
ables evaluated were extent of resection and whether adjuvant
hepatic-arterial infusional chemotherapy (HAIC) was adminis-
tered. Accurate documentation of post-operative systemic chemo-
therapy in other patients was not available. The extent of the
resection was recorded as major or minor, with a major resection
defined as a resection of more than two segments. Post-operative
follow-up included physical examination and cross-sectional
imaging every 4 to 6 months.
Statistical analysis
Statistical analyses were performed with the software package JMP
(JMP, Cary, NC, USA) and R (http://www.r-project.org). Disease-
specific survival (DSS) was calculated from the time of initial
hepatectomy until cancer-related death. Survival curves were gen-
erated using the Kaplan–Meier method, with patients censored
when lost to follow-up or upon death from non-cancer causes.
Kaplan–Meier estimates of survival and Cox’s proportional
hazards models were then used to explore differences in survival
among the strata established by the CRS,6 the MSKCC nomo-
gram16 and the Nordlinger system.34 Conditional survival esti-
mates represent the probability that a patient will survive an
additional number of years, given that the patient has already
survived a given amount of time. Conditional survival probabili-
ties were calculated using Bayes’ rule and Kaplan–Meier estimates
of unconditional survival. Univariate analysis for factors associ-
ated with DSS was conducted using the log-rank test. Variables
significant at the 0.1 level were included in a multivariable Cox’s
proportional regression model. P-values <0.05 were considered
statistically significant.
Results
Demographics and treatment
From January 1994 through to December 2004, a total of 951
patients underwent an initial hepatectomy for colorectal liver
metastases. Of these, the 10 post-operative deaths (1%) and
the 134 patients (14%) with positive margins were excluded. The
remaining 807 patients make up the study population. The
median follow-up for survivors, as measured from the time of
hepatectomy, was 87 months. At last follow-up, 389 (48%)
patients had died of the disease, 66 (8%) had died of other causes,
60 (7%) were alive with the disease and 292 (36%) were alive with
no evidence of disease.
The demographic and tumor-related characteristics of the
whole cohort of 807 patients are listed in Table 1. Most primary
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tumours were of advanced T stage [T3/T4 in 626 (78%) patients)
and node positive (482 patients (60%)]. Ninety-seven patients
(12%) presented with liver metastases at the time of diagnosis of
their colorectal primary (synchronous disease). The majority
(70%) of patients had a low CRS (score 0–2). Four per cent
of the patients had extrahepatic metastases; these sites were
resected at the time of the hepatectomy. A combined resection of
the colorectal primary and liver metastases was performed in 44
of 97 patients (45%). Four hundred and eighty-four (60%)
patients experienced recurrence, of which 198 (41%) occurred
within the first year and 356 (74%) by 2 years after the liver
resection.
Conditional survival
Actuarial DSS was 68% at 5 years and 55% at 10 years. For those
patients alive 1 year after the liver resection, the probability of
surviving to 5 and 10 years after a liver resection increased to 70%
and 56%, respectively (See Fig. 1a). For 3-year survivors, the prob-
ability of surviving to 5 and 10 years after a liver resection
increased to 80% and 65%, respectively. Of the 345 patients (43%
of the original cohort of 807 patients) who survived to 5 years, the
probability of surviving to 10 years was 81%.
The conditional survival for patients surviving without recur-
rence was higher than for all survivors. For those patients alive and
recurrence free 1 year after a liver resection, the probabilities of
surviving to 5 and 10 years after a liver resection were 78% and
64%, respectively (See Fig. 1b). For 3-year recurrence-free survi-
vors, the probability of surviving to 5 and 10 years after a liver
resection increased to 98% and 86%, respectively. Of the 211
patients (26% of the original cohort of 807 patients) who survived
without recurrence to 5 years, the probability of surviving to 10
years was 95%.
Conditional survival and the clinical risk score
for survivors
At baseline, patients with a high and low CRS had significantly
different DSS (Fig. 2a, P < 0.0005). However, as survival time after
liver resection increased, the difference in prognosis between the
two groups decreased such that, among 3-year survivors, there was
no significant difference in conditional survival between patients
with a high and low CRS (Fig. 2b–d).
Analyses were performed to identify factors associated with
further DSS for the 504 patients who had survived 3 years post-
operatively (Table 2). Factors associated with further survival on
univariate analysis included nodal status of the primary tumour,
perineural invasion, the disease-free interval between diagnosis of
the primary tumor and hepatic metastasis, CEA level and whether
tumour recurrence had occurred within 3 years of the liver resec-
tion. On multivariate analysis, there were three independent
factors associated with worse DSS: recurrence within 3 years of the
liver resection [hazard ratio (HR) 8.6, 95% confidence interval
(CI) 5.6–13.7], CEA > 200 ng/ml (HR 2.1, 95% CI 1.2–3.8) and
Table 1 Patient demographics
Variable Value
Gender
Male 466 (58%)
Female 341 (42%)
Age
Median age (years, range) 63 (23–89)
>70 years old 200 (25%)
Primary site
Colon 582 (72%)
Rectum 225 (28%)
T stage of primary tumour
1 25 (3%)
2 104 (13%)
3 586 (73%)
4 40 (5%)
Unknown 52 (6%)
N stage of primary tumour
N0 325 (40%)
N1,2 482 (60%)
Lymphovascular invasion of primary tumour
Present 356 (44%)
Absent 199 (25%)
Unknown 252 (31%)
Perineural invasion of primary tumour
Present 389 (48%)
Absent 96 (12%)
Unknown 322 (40%)
Tumour grade of primary tumour
Low 21 (3%)
Moderate 635 (79%)
Poor 67 (8%)
Unknown 84 (10%)
Disease-free interval, months
0–12 444 (55%)
>12 363 (45%)
Size of largest metastasis, cm
<5 554 (69%)
5 253 (31%)
Number of liver metastases
1 397 (49%)
>1 410 (51%)
Pre-operative CEA level, ng/ml
<200 642 (80%)
200 76 (9%)
Unknown 89 (11%)
Clinical Risk Score
0 55 (7%)
1 239 (30%)
2 267 (33%)
3 184 (23%)
4 51 (6%)
5 11 (1%)
Clinical Risk Score: low versus high
Low (0–2) 561 (70%)
High (3–5) 246 (30%)
Extent of liver resection
Minor 319 (40%)
Major 488 (60%)
Extrahepatic disease resected
Yes 32 (4%)
No 775 (96%)
Peri-operative chemotherapy
Neoadjuvant 179 (22%)
Adjuvant
Systemic 654 (81%)
HAI + systemic 208 (26%)
CEA, carcinoembryonic antigen; HAI, hepatic arterial infusion.
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disease-free interval < 12 months between the diagnosis of the
primary tumour and hepatic metastasis (HR 1.4, 95% CI 1.0–2.1).
Conditional survival and the clinical risk score for
recurrence-free survivors
A separate analysis was performed to examine conditional sur-
vival in the subset of survivors whose disease had not recurred. At
1 year recurrence-free survival after a liver resection and at all
subsequent time points, the conditional survival of patients with a
high and low CRS were not statistically significant (Fig. 3). For
1-year recurrence-free survivors, factors associated with further
DSS on univariate analysis were perineural invasion, nodal status
of the primary tumour, CEA level and the size of the largest
hepatic metastasis (see Table 3). However, on multivariate analy-
sis, no independent factors associated with DSS were found.
In contrast to the lack of prognostic significance of traditional
clinical variables, tumour recurrence within the first year after a
liver resection was highly associated with worse DSS (Fig. 4). For
those patients who were recurrence-free at 1 year post-operatively,
the probability of surviving to 10 years post-operatively was 64%,
compared with 24% for those patients who had recurred within
the first year after a liver resection (P < 0.0001).
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Figure 1 Conditional disease-specific survival for all survivors (a); and recurrence-free survivors (b)
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The MSKCC nomogram
A similar analysis was performed using the MSKCC nomogram.16
Patients were divided evenly into quartiles based on their pre-
dicted DSS, and, at baseline, these quartiles had significantly dif-
ferent survivals (Fig. 5a, P < 0.01). However, in spite of the
baseline concordance index for the nomogram (0.587) being
superior to that of the CRS (0.551), the nomogram could not
provide prognostic discrimination between the quartiles for
3-year survivors (P = 0.12, data not shown). For recurrence-free
survivors, at 1 year post-operatively, there was only a significantly
different DSS for patients in the first versus the fourth quartile
(P = 0.004), which was lost at 2 years of recurrence-free survival
(Fig. 6, P = 0.42).
In contrast to the lack of prognostic significance of traditional
clinical variables, tumour recurrence within the first year after a
liver resection was highly associated with worse DSS (Fig. 4). For
those patients who were recurrence-free at 1 year post-operatively,
the probability of surviving to 10 years post-operatively was 64%,
compared with 24% for those patients who had recurred within
the first year after a liver resection (P < 0.0001).
At baseline, the Nordlinger system did not provide prognostic
stratification in our patient population (P = 0.61, data not shown).
Discussion
This study demonstrates that baseline clinico-pathological risk
factors, whether combined into prognostic scoring systems or not,
have little prognostic discriminatory value for even short-term
survivors after a resection of colorectal liver metastases. This is
most dramatically demonstrated for those patients who are alive
without recurrence just 1 year post-operatively, at which time
those patients with a baseline poor prognosis have the same DSS
as those with a baseline good prognosis.
The main clinical utility of conditional survival analyses is in
counselling patients who have already accumulated a survival
time after treatment of their cancer. Similar to studies in other
cancers,28,31,32,35–37 this study of patients who had undergone a
margin-negative liver resection for colorectal metastasis found
that, as survival time increased, so too did the probability of future
survival. For a population of patients who, pre-operatively, have
an approximately 25% chance of a 10-year survival, it is clinically
meaningful, for example, to be able to advise 1-, 3- and 5-year
survivors that their chance of reaching the 10-year survival time
point has increased to 56%, 65% and 81%, respectively.
Although the CRS has been shown in most studies to stratify
patients by outcome, its CI remains low (0.6),15 meaning that
some patients with low CRS recur early, whereas those with a high
CRS are not precluded from long-term survival or even a cure.
This reflects the imperfect nature of clinico-pathological variables
as surrogate markers of tumour biology. The analysis of the rela-
tionship between the CRS and conditional survival in the present
study emphasizes this point. By 3 years of post-operative survival,
prognostic stratification of the CRS is lost, and on multivariate
analysis, while two pre-operative clinical variables (disease-free
Figure 2 Disease-specific survival stratified by a low or high clinical risk score (CRS) at baseline (a), 1 year (b), 2 years (c) and 3 years (d)
post-operatively
HPB 807
HPB 2013, 15, 803–813 © 2013 International Hepato-Pancreato-Biliary Association
Table 2 Factors associated with disease-specific survival after 3-year survival
Factor (n) 5-year conditional
DSSa (%)
Univariate
P
Multivariate
P, HR (95% CI)
Gender 0.73 –
Female (n = 214) 65
Male (n = 290) 69
Age, years 0.54 –
70 (n = 381) 66
>70 (n = 123) 72
Primary site 0.46 –
Colon (n = 373) 69
Rectum (n = 166) 65
T stage of primary tumour 0.79 –
1, 2 (n = 89) 70
3, 4 (n = 389) 67
N stage of primary tumour 0.09 0.56
N0 (n = 232) 72
N1,2 (n = 272) 64
Lymphovascular invasion of primary tumour 0.47 –
Present (n = 115) 64
Absent (n = 258) 71
Perineural invasion of primary tumour 0.05 0.83
Present (n = 59) 53
Absent (n = 272) 71
Tumour grade of primary tumour 0.54 –
Low (n = 15) 65
Moderate (n = 413) 67
Poor (n = 32) 63
DFI before liver metastasis, months 0.07 0.04, 1.4 (1.0–2.1)
0–12 (n = 277) 63
>12 (n = 227) 73
Size of largest metastasis, cm 0.16 –
<5 (n = 370) 69
5 (n = 134) 63
Number of liver metastases 0.67 –
1 (n = 269) 69
>1 (n = 235) 65
Extent of liver resection 0.91 –
Minor (n = 215) 67
Major (n = 289) 68
Extrahepatic disease resected 0.45 –
Yes (n = 14) 67
No (n = 490) 80
Pre-operative CEA level, ng/ml 0.005 <0.01, 2.1 (1.2–3.8)
<200 (n = 421) 70
200 (n = 37) 45
Clinical Risk Score: 0.19 –
Low (0–2) (n = 386) 69
High (3–5) (n = 118) 62
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interval and CEA level) remain significant, it is the tumor’s most
recent biological history, namely evidence of recurrence after a
liver resection, that is the most significant independent prognostic
variable.
There is only one other study that examined conditional sur-
vival in patients who had undergone a resection for colorectal liver
metastasis.20 This was a study of 949 patients from five hepatobil-
iary centres in the United States and Europe. Unlike the present
study, 9% of patients had positive margins. Their study period of
1982–2008 bridged the introduction of modern chemotherapy in
the mid-1990s. Details of patient treatment other than their resec-
tion, as well as tumour recurrence were not included. Their
primary outcome measure was overall survival, whereas in this
study, disease-specific survival was utilized. Therefore, as the
present study comprises a more modern, margin-negative popu-
lation with cancer-specific death as the primary endpoint, it may
provide more accurate data for post-operative counselling. The
study of Nathan et al.20 also compared three prognostic scoring
systems: the CRS, the Nordlinger system and the MSKCC nomo-
gram. Similar to our study, they found that the CRS and the
MSKCC nomogram had poor-to-moderate discriminatory capac-
ity at baseline (CI < 0.6 for both). This prognostic ability also
decreased with increasing survival after a liver resection, although
the time point at which all prognostic stratification was lost was
not stated. The Nordlinger system in their study had a prognostic
value at baseline that appeared to increase with survival time.
However, in the present study, the Nordlinger system did not have
a prognostic value even at baseline. Finally, in the Nathan et al.20
study, the prognostic value of early post-operative recurrence on
future survival could not be examined.
The value of clinico-pathological variables in conditional sur-
vival analyses has been studied in other cancers. Studies in
primary colon cancer,28 lymphoma32 and retroperitoneal sar-
coma31,33 found that survival projections based on initial prognos-
tic measures, akin to the CRS, converge with increased survival
time. This convergence demonstrates that the baseline prognostic
variables become less valuable over time. A recent study by Harsh-
man et al.35 in patients with metastatic renal cell carcinoma
treated with VEGF-targeted therapy demonstrated contrary find-
ings. With a median follow-up of 20 months, the prognostic
stratification of these patients into favourable, intermediate and
poor risk groups remained significant (P < 0.0001) at 18 months.
In contrast to the previous studies and the present one where
Table 2 Continued
Factor (n) 5-year conditional
DSSa (%)
Univariate
P
Multivariate
P, HR (95% CI)
Pre-liver resection chemotherapy 0.45
Yes (n = 391) 64
No (n = 107) 68 –
Adjuvant systemic chemotherapy 0.69 –
Yes (n = 433) 68
No (n = 47) 63
Adjuvant hepatic arterial chemotherapy 0.81 –
Yes (n = 160) 65
No (n = 336) 69
Recurrence within 3 years of a liver resection <0.0001 <0.0001, 8.6 (5.6–13.7)
Yes (n = 232) 38
No (n = 272) 90
aDefined as the probability of surviving another 5 years, having already survived 3 years.
DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; DFI, disease-free interval.
Figure 3 Disease-specific survival of patients who were recurrence
free at 1 year post-operatively, stratified by low or high clinical risk
score (CRS)
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Table 3 Factors associated with disease-specific survival after 1 year of recurrence-free survival
Factor (n) 5-year conditional
DSSa (%)
Univariate
P
Multivariate P,
HR (95% CI)
Gender 0.72 –
Female (n = 222) 70
Male (n = 317) 73
Age, years 0.20 –
70 (n = 404) 70
>70 (n = 135) 76
Primary site 0.27 –
Colon (n = 373) 73
Rectum (n = 166) 68
T stage of primary tumour 0.17 –
1, 2 (n = 95) 73
3, 4 (n = 415) 70
N stage of primary tumour 0.04 0.10
N0 (n = 238) 74
N1,2 (n = 301) 69
Lymphovascular invasion of primary tumour 0.58 –
Present (n = 117) 71
Absent (n = 267) 74
Perineural invasion of primary tumour 0.02 0.12
Present (n = 56) 62
Absent (n = 285) 74
Tumour grade of primary tumour 0.81 –
Low (n = 18) 65
Moderate (n = 431) 71
Poor (n = 36) 76
Disease-free interval, months 0.11 –
0–12 (n = 241) 75
>12 (n = 298) 69
Size of largest metastasis, cm 0.07 0.19
<5 (n = 385) 73
5 (n = 154) 67
Number of liver metastases 0.47 –
1 (n = 291) 72
>1 (n = 248) 72
Extent of liver resection 0.73 –
Minor (n = 232) 72
Major (n = 307) 72
Extrahepatic disease resected 0.67 –
Yes (n = 13) 67
No (n = 526) 72
Pre-operative CEA level, ng/ml 0.06 0.27
<200 (n = 440) 74
200 (n = 43) 57
Clinical Risk Score: 0.1 –
Low (0–2) (n = 405) 73
High (3–5) (n = 134) 68
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conditional survival was analysed after potentially curative treat-
ment (surgical resection for colon cancer and sarcoma, chemo-
therapy for lymphoma), patients in the study of Harshman et al.35
were treated with palliative chemotherapy. This difference in the
goals (and efficacy) of treatment points to the impact of poten-
tially curative therapy in altering the course of the disease.
As demonstrated in multiple retrospective series,38–44 recurrence
after a resection for colorectal liver metastases occurs in 40–74%
of patients, and is associated with a worse outcome. In the present
study, the overall recurrence rate of 60%, with 40% of recurrences
within the first year, is consistent with the published literature. A
recent study from our institution3 examining the effect of recur-
rence on outcome found that a worse outcome was associated
with a shorter time both between primary presentation and a
hepatectomy and between a hepatectomy and recurrence, multi-
ple sites of recurrence, non-lung recurrence, and inability to resect
recurrent disease. In the present study, we found that in 3-year
survivors, recurrence within 3 years was the most important inde-
pendent prognostic variable associated with future DSS on mul-
tivariate analysis, with a HR 8.6. Two-thirds of patients who are
recurrence free at 1 year and over 80% of patients recurrence free
at 3 years will still be alive 10 years after a liver resection. This
contrasts sharply with 10 year DSS of 24% and 38% for those who
recur within 1 and 3 years, respectively. The novel and clinically
useful finding from this study is that baseline (pre-operative)
measures of poor prognosis are no longer discriminatory after just
1 year of recurrence-free survival. These data are useful and
informative for physicians counselling patients in the years after a
liver resection. From a research perspective, comparison of
Table 3 Continued
Factor (n) 5-year conditional
DSSa (%)
Univariate
P
Multivariate P,
HR (95% CI)
Pre-liver resection chemotherapy 0.58 –
Yes (n = 98) 72
No (n = 434) 71
Adjuvant systemic chemotherapy 0.98 –
Yes (n = 450) 72
No (n = 60) 75
Adjuvant hepatic arterial chemotherapy 0.95 –
Yes (n = 156) 71
No (n = 372) 73
aDefined as the probability of surviving another 5 years, having already survived 1 year without recurrence.
DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen.
Figure 4 Disease-specific survival at 1 year post-operatively, strati-
fied by recurrence within the first post-operative year
Figure 5 Disease-specific survival stratified by nomogram quartiles,
at baseline
HPB 811
HPB 2013, 15, 803–813 © 2013 International Hepato-Pancreato-Biliary Association
patients who recur early with those who do not may facilitate
identification of new prognostic biomarkers.
The retrospective nature of this study produces several impor-
tant limitations. First, there is missing data, especially regarding
the pathological details of the primary tumour. The T stage and
level of differentiation were unknown in 6% and 10%, respec-
tively, with LVI and PNI unknown in 30–40%. While these vari-
ables are not part of the CRS, recent studies suggest that the
histopathological features of the primary tumour may be more
prognostic than characteristics of the liver metastases.13,45 Second,
treatment regimens, especially use of neoadjuvant chemotherapy,
cannot be standardized outside of the confines of a clinical trial.
Thus, it is impossible to interpret the lack of a prognostic value of
chemotherapy from this study.
In conclusion, conditional survival analyses provide useful
prognostic information for counselling patients who have sur-
vived years after resection of colorectal liver metastasis. However,
our ability to predict future survival after the survival time has
been accrued remains poor, as demonstrated by the loss of the
prognostic value of the CRS after 3 years of disease-specific sur-
vival and 1 year of recurrence-free survival. The presence or
absence of recurrence appears to be the most useful single clinical
feature in estimating conditional DSS.
Conflicts of interest
None declared.
References
1. House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP et al. (2010)
Survival after hepatic resection for metastatic colorectal cancer: trends in
outcomes for 1,600 patients during two decades at a single institution.
J Am Coll Surg 210:744–752, 52–5.
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M
et al. (2007) Actual 10-year survival after resection of colorectal liver
metastases defines cure. J Clin Oncol 25:4575–4580.
3. D'Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH
et al. (2011) Effect on outcome of recurrence patterns after hepatectomy
for colorectal metastases. Ann Surg Oncol 18:1096–1103.
4. Ambiru S, Miyazaki M, Isono T, Ito H, Nakagawa K, Shimizu H et al. (1999)
Hepatic resection for colorectal metastases: analysis of prognostic
factors. Dis Colon Rectum 42:632–639.
5. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R,
Schulick RD et al. (2002) Trends in long-term survival following liver
resection for hepatic colorectal metastases. Ann Surg 235:759–766.
6. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. (1999) Clinical
score for predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg
230:309–318; discussion 18–21.
7. Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A,
Kobayashi A et al. (2001) A study of factors influencing prognosis after
resection of hepatic metastases from colorectal and gastric carcinoma.
Am J Gastroenterol 96:3178–3184.
8. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC
et al. (1999) Hepatic resection for metastatic colorectal adenocarcinoma:
a proposal of a prognostic scoring system. J Am Coll Surg 189:291–299.
9. Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S,
Makuuchi M. (2007) Simplified staging system for predicting the progno-
sis of patients with resectable liver metastasis: development and valida-
tion. Arch Surg 142:269–276; discussion 77.
10. Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. (2005)
Analysis of preoperative prognostic factors for long-term survival after
hepatic resection of liver metastasis of colorectal carcinoma. J Gastroin-
test Surg 9:374–380.
11. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. (1995) Resection of
colorectal liver metastases. World J Surg 19:59–71.
12. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. (2005) Prog-
nostic scoring in colorectal cancer liver metastases: development and
validation. Arch Surg 140:183–189.
13. Tan MC, Castaldo ET, Gao F, Chari RS, Linehan DC, Wright JK et al.
(2008) A prognostic system applicable to patients with resectable liver
metastasis from colorectal carcinoma staged by positron emission tom-
ography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor vari-
ables. J Am Coll Surg 206:857–868; discussion 68–9.
14. Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Togo S. (2007) Long-
term characteristics of 5-year survivors after liver resection for colorectal
metastases. Ann Surg Oncol 14:1336–1346.
15. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM
et al. (2007) Hepatic resection for colorectal metastases: value for risk
scoring systems? Ann Surg 246:183–191.
Figure 6 Disease-specific survival for recurrence-free survivors at 1 year (a) and 2 years (b) post-operatively, stratified by nomogram quartiles
812 HPB
HPB 2013, 15, 803–813 © 2013 International Hepato-Pancreato-Biliary Association
16. Kattan MW, Gonen M, Jarnagin WR, DeMatteo R, D'Angelica M, Weiser
M et al. (2008) A nomogram for predicting disease-specific survival after
hepatic resection for metastatic colorectal cancer. Ann Surg 247:282–
287.
17. Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. (2002) Hepatic
resection for colorectal metastases: can preoperative scoring predict
patient outcome? World J Surg 26:1348–1353.
18. Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. (2004) The
clinical risk score: emerging as a reliable preoperative prognostic
index in hepatectomy for colorectal metastases. Arch Surg 139:1168–
1172.
19. Reddy SK, Kattan MW, Yu C, Ceppa EP, de la Fuente SG, Fong Y et al.
(2009) Evaluation of peri-operative chemotherapy using a prognostic
nomogram for survival after resection of colorectal liver metastases. HPB
11:592–599.
20. Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G et al.
(2010) Conditional survival after surgical resection of colorectal liver
metastasis: an international multi-institutional analysis of 949 patients.
J Am Coll Surg 210:755–764, 64-6.
21. Ellison LF, Bryant H, Lockwood G, Shack L. (2011) Conditional survival
analyses across cancer sites. Health Rep 22:21–25.
22. Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH,
Brenner H et al. (2010) Clinical relevance of conditional survival of cancer
patients in europe: age-specific analyses of 13 cancers. J Clin Oncol
28:2520–2528.
23. Merrill RM, Hunter BD. (2010) Conditional survival among cancer patients
in the United States. Oncologist 15:873–882.
24. Yu XQ, Baade PD, O'Connell DL. (2012) Conditional survival of cancer
patients: an Australian perspective. BMC Cancer 12:460.
25. Merrill RM, Henson DE, Ries LA. (1998) Conditional survival estimates in
34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum
41:1097–1106.
26. Wang SJ, Fuller CD, Emery R, Thomas CR. (2007) Conditional survival in
rectal cancer: a SEER database analysis. Gastrointest Cancer Res 1:84–
89.
27. Wang SJ, Wissel AR, Luh JY, Fuller CD, Kalpathy-Cramer J, Thomas CR,
Jr. (2011) An interactive tool for individualized estimation of conditional
survival in rectal cancer. Ann Surg Oncol 18:1547–1552.
28. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC et al.
(2010) Conditional survival and the choice of conditioning set for patients
with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin
Oncol 28:2544–2548.
29. Kent TS, Sachs TE, Sanchez N, Vollmer CM, Jr, Callery MP. (2011)
Conditional survival in pancreatic cancer: better than expected. HPB
13:876–880.
30. Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM et al.
(2012) Conditional survival in patients with pancreatic ductal adenocar-
cinoma resected with curative intent. Cancer 118:2674–2681.
31. Abbott AM, Habermann EB, Parsons HM, Tuttle T, Al-Refaie W. (2012)
Prognosis for primary retroperitoneal sarcoma survivors: a conditional
survival analysis. Cancer 118:3321–3329.
32. Moller MB, Pedersen NT, Christensen BE. (2006) Conditional survival of
patients with diffuse large B-cell lymphoma. Cancer 106:2165–2170.
33. Parsons HM, Habermann EB, Tuttle TM, Al-Refaie WB. (2011) Conditional
survival of extremity soft-tissue sarcoma: results beyond the staging
system. Cancer 117:1055–1060.
34. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P
et al. (1996) Surgical resection of colorectal carcinoma metastases to the
liver. A prognostic scoring system to improve case selection, based on
1568 patients. Association Francaise de Chirurgie.Cancer 77:1254–1262.
35. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L
et al. (2012) Conditional survival of patients with metastatic renal-cell
carcinoma treated with VEGF-targeted therapy: a population-based
study. Lancet Oncol 13:927–935.
36. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P
et al. (2009) Conditional survival predictions after nephrectomy for renal
cell carcinoma. J Urol 182:2607–2612.
37. Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML
et al. (2007) Dynamic outcome prediction in patients with clear cell renal
cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
J Urol 177:477–480.
38. Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. (1987) Patterns of
failure following surgical resection of colorectal cancer liver metastases.
Rationale for a multimodal approach. Ann Surg 205:264–270.
39. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG et al.
(1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946.
40. Metcalfe M, Mann C, Mullin E, Maddern G. (2005) Detecting curable
disease following hepatectomy for colorectal metastases. Aust N Z J
Surg 75:524–527.
41. Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van
Coevorden F. (2005) Prognostic factors and evaluation of surgical man-
agement of hepatic metastases from colorectal origin: a 10-year single-
institute experience. J Gastrointest Surg 9:178–186.
42. Takahashi S, Inoue K, Konishi M, Nakagouri T, Kinoshita T. (2003) Prog-
nostic factors for poor survival after repeat hepatectomy in patients with
colorectal liver metastases. Surgery 133:627–634.
43. Topal B, Kaufman L, Aerts R, Penninckx F. (2003) Patterns of failure
following curative resection of colorectal liver metastases. Eur J Surg
Oncol 29:248–253.
44. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K.
(2004) Predictors of extrahepatic recurrence after resection of colorectal
liver metastases. Br J Surg 91:327–333.
45. Cardona K, Mastrodomenico P, D'Amico F, Shia J, Gonen M, Weiser MR
et al. (2013) Detailed pathologic characteristics of the primary colorectal
tumor independently predict outcome after hepatectomy for metastases.
Ann Surg Oncol 20:148–154.
HPB 813
HPB 2013, 15, 803–813 © 2013 International Hepato-Pancreato-Biliary Association
